11 results
To study whether pretreatment with metformin can reduce myocardial injury during CABG surgery in patients without diabetes mellitus.
The primary objective of the phase I part of the study is to determine the recommended phase II dose of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced ovarian cancer. The secondary objectives the phase I…
To study the protective effect of pre-treatment with metformin on flow mediated dilation after 20 minutes ischemia and 20 minutes reperfusion. If metformin treatment indeed limits endothelial IR-injury, a second study will be performed in the same…
To study whether dipyridamole reduces gastrointestinal absorption of metformin.
We aim to compare the effectiveness, feasibility and safety of both metformin and sitagliptin in patients with TIA or minor ischemic stroke and impaired glucose tolerance. Furthermore, we will assess whether a slow increase in dose of metformin over…
Primary objective: To evaluate the effect of treatment with oral hypoglycemic agents (OHA) on the incidence of large-for-gestational-age (LGA) infants in women with GDM requiring medication, compared to insulin (INS) treatment.Secondary objectives:…
Primary objectives:Phase 1: To determine the MTD and/or RP2D of oral ponatinib administered QD in pediatric participants with selected advanced hematologic malignancies or solid tumors.Phase 2- Group A (CP-CML): To determine the efficacy of oral…
The primary objective of this study is to determine the clinical efficacy of doxycycline and metformin compared with the standard treatment with doxycycline alone after 24 weeks of treatment.
This study is an open-label, non-randomized extension to study CCDZ173X2201. It aims to provide treatment with CDZ173 to patients withAPDS/PASLI who participated in study CCDZ173X2201 or who were treated previously with PI3Kδ inhibitors other than…
Primary: To assess the proportion of patients with intervention failure at 12 months after dose reduction, defined as patients who have restarted their initial dose due to (expected) loss of major molecular response.
Objective: We aim to optimize the application of an existing drug, metformin, for a new indication, AiWG, by showing that metformin in combination with lifestyle interventions reduces AiWG compared to placebo in combination with lifestyle…